Thrivent Financial for Lutherans
ALLO icon

Thrivent Financial for Lutherans’s Allogene Therapeutics ALLO Stock Holding History

Thrivent Financial for Lutherans’s Portfolio ALLO Stock Details ALLO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-129,535
Closed -$644K – 2430
2023
Q2 		$644K Sell
129,535
-160,972
-55% -$871K ﹤0.01% 2074
2023
Q1 		$1.44M Sell
290,507
-166,369
-36% -$1.07M ﹤0.01% 1548
2022
Q4 		$2.87M Buy
456,876
+290,286
+174% +$2.69M 0.01% 1030
2022
Q3 		$1.8M Buy
166,590
+123,176
+284% +$1.67M ﹤0.01% 1284
2022
Q2 		$494K Sell
43,414
-37,873
-47% -$336K ﹤0.01% 2098
2022
Q1 		$740K Sell
81,287
-75,052
-48% -$782K ﹤0.01% 1998
2021
Q4 		$2.33M Buy
156,339
+102,160
+189% +$1.8M ﹤0.01% 1284
2021
Q3 		$1.39M Buy
54,179
+12,824
+31% +$304K ﹤0.01% 1612
2021
Q2 		$1.08M Buy
+41,355
New +$1.18M ﹤0.01% 1788

Other funds holding ALLO

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $3.68B AUM 14.99% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Thrivent Financial for Lutherans's ALLO Position: Q3 2023 in Review

Thrivent Financial for Lutherans sold out of Allogene Therapeutics (ALLO) in Q3 2023, closing a stake of 129,535 shares — an estimated $644K sold.

Thrivent Financial for Lutherans first reported a position in ALLO in Q2 2021 and held it in 9 quarters. The position peaked at $2.87M in Q4 2022. 154 funds tracked by Wall St. Rank hold ALLO as of Q3 2023.

  • Thrivent Financial for Lutherans reported no remaining Allogene Therapeutics position as of Q3 2023 after selling out during the quarter.
  • Thrivent Financial for Lutherans sold 129,535 Allogene Therapeutics shares in Q3 2023, an estimated $644K.
  • Thrivent Financial for Lutherans first reported a position in Allogene Therapeutics in Q2 2021 and held it in 9 quarters.
  • Thrivent Financial for Lutherans's Allogene Therapeutics position peaked at $2.87M in Q4 2022.
  • 154 funds tracked by Wall St. Rank held Allogene Therapeutics as of Q3 2023.

Based on Thrivent Financial for Lutherans's 13F filing for Q3 2023, filed 14 Nov 2023.